Table 3. Baseline characteristics of included patients (n=500).
Legend: BMI, body mass index; CrCl, creatinine clearance; CG, Cockroft-Gault; NSAIDs, nonsteroidal anti-inflammatory drugs.* Data are presented as a proportion, unless otherwise noted.º Presence of patients with missing data: 3 for BMI and 93 for liver enzymes.¹ Other care units: gastroenterology, nephrology, geriatrics, hematology, ORL, orthopedics, urology, rheumatology, psychiatry and palliative care
| Characteristics | n (%) * | |
| Age (years), mean +- SD | 74.3 +- 11.5 | |
| Male gender | 262 (52.4) | |
| BMI (kg/m2)o | < 18.5 | 12 (2.4) |
| 18.5 - 24.9 | 132 (26.6) | |
| 25.0 - 29.9 | 164 (33.0) | |
| > 30.0 | 189 (38.0) | |
| Hospitalization data | ||
| Length of stay, median; range (days) | 5; 1 - 70 | |
| Health Care units | Cardiology | 205 (41.0) |
| Internal medicine | 107 (21.4) | |
| Family medicine | 85 (17.0) | |
| Neurology | 43 (8.6) | |
| Surgery | 22 (4.4) | |
| Respirology | 17 (3.4) | |
| Others1 | 21 (4.2) | |
| Laboratory data | ||
| CrCl (CG), median; range (mL/min) o | 63.9; 20.4 - 120.0 | |
| CrCl < 30 mL/min | 11 (2.2) | |
| Level of liver enzymes o | AST, median ; range (U/L) | 21; 8-155 |
| ALT, median ; range (U/L) | 17; 5-529 | |
| Clinical data | ||
| Atrial flutter | 79 (15.8) | |
| Valvular AF | 13 (2.6) | |
| Mitral stenosis | Mild to moderate | 25 (5.0) |
| Moderate to severe | 5 (1.0) | |
| Biological heart valve | 13 (2.6) | |
| Congestive heart failure | 183 (36.6) | |
| Hypertension | 397 (79.4) | |
| Diabetes | 157 (31.4) | |
| Stroke | 139 (27.8) | |
| Atherosclerotic heart disease | 212 (42.4) | |
| Atherosclerotic vascular disease | 84 (16.8) | |
| Cirrhosis | 5 (5.2) | |
| CHADS2 > 1 | 473 (94.6) | |
| CHADS2-VA2Sc > 2 | 455 (91.0) | |
| Drugs | ||
| Number of drugs at discharge, median ; range | 10 ; 2 - 8 | |
| Antiplatelets | 82 (16.4) | |
| NSAIDs | 30 (6.0) | |
| DOACs user,s type | Prevalent | 317 (63.4) |
| Incident | 148 (29.6) | |
| Switch | 35 (7.0) |